/
We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products focused on women s health and well-being through early detection and treatment. We sell and service our products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.
17.42% operating margin is respectable but not wide. ROIC at 7.75%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 1.7%, essentially flat. Margins also contracted 4.5pp. This is a business that needs a catalyst.
Free cash flow declined 18% versus the prior year, cash generation momentum has weakened. ROIC dropped from 10.33% to 7.75%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$4.13B
▲ +1.7% YoY
Net Income (TTM)
$544M
▼ -28.3% YoY
Op. Margin
17.48%
▼ -4.5pp YoY
ROIC
8.04%
▼ -2.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.04B
▼ -17.7% YoY
Op. Cash Flow (TTM)
$1.10B
▼ -17.7% YoY
Net Debt
$156M
Cash & Equiv.
$2.36B
5Y CAGR: +1.7%
5Y CAGR: +4.6%
Continue Research